p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1‐NF‐κB pathway in human ovarian cancer cells

Platinum‐based therapeutic strategies have been widely used in ovarian cancer treatment. However, drug resistance has greatly limited therapeutic efficacy. Recently, tolerance to cisplatin has been attributed to other factors unrelated to DNA. p62 (also known as SQSTM1) functions as a multifunctiona...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Yan, Xiao‐Yu, Zhang, Yu, Zhang, Juan‐Juan, Zhang, Li‐Chao, Liu, Ya‐Nan, Wu, Yao, Xue, Ya‐Nan, Lu, Sheng‐Yao, Su, Jing, Sun, Lian‐Kun
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5497928/
https://ncbi.nlm.nih.gov/pubmed/28498503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13276
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados